Chemistry:Bay 11-7082
From HandWiki
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C10H9NO2S |
| Molar mass | 207.25 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bay 11-7082 is an experimental drug which acts as an inhibitor of the NFκB pathway and the NLRP3 inflammasome. It has antiinflammatory effects and has potential applications in the treatment of conditions such as dermatitis, COVID-19, irritable bowel syndrome and certain forms of cancer.[1][2][3][4][5][6]
See also
References
- ↑ "Potential roles of the NFκB and glutathione pathways in mature human erythrocytes". Cellular & Molecular Biology Letters 17 (1): 11–20. March 2012. doi:10.2478/s11658-011-0032-x. PMID 22105338.
- ↑ "Inflammasome as a promising therapeutic target for cancer". Life Sciences 231. August 2019. doi:10.1016/j.lfs.2019.116593. PMID 31228512.
- ↑ "Pharmacological Inhibitors of the NLRP3 Inflammasome". Frontiers in Immunology 10: 2538. 2019. doi:10.3389/fimmu.2019.02538. PMID 31749805.
- ↑ "Inflammasome Activation in Pollution-Induced Skin Conditions". Plastic and Reconstructive Surgery 147 (1S–2): 15S–24S. January 2021. doi:10.1097/PRS.0000000000007617. PMID 33347070.
- ↑ "NF-κB signalling as a pharmacological target in COVID-19: potential roles for IKKβ inhibitors". Naunyn-Schmiedeberg's Archives of Pharmacology 394 (3): 561–567. March 2021. doi:10.1007/s00210-020-02035-5. PMID 33394134.
- ↑ "The Role and the Regulation of NLRP3 Inflammasome in Irritable Bowel Syndrome: A Narrative Review". Microorganisms 13 (1): 171. January 2025. doi:10.3390/microorganisms13010171. PMID 39858939.
 |  |
